BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 17595247)

  • 1. A novel tyrosine-kinase selective inhibitor, sunitinib, induces transient hypothyroidism by blocking iodine uptake.
    Mannavola D; Coco P; Vannucchi G; Bertuelli R; Carletto M; Casali PG; Beck-Peccoz P; Fugazzola L
    J Clin Endocrinol Metab; 2007 Sep; 92(9):3531-4. PubMed ID: 17595247
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sunitinib-induced hypothyroidism is due to induction of type 3 deiodinase activity and thyroidal capillary regression.
    Kappers MH; van Esch JH; Smedts FM; de Krijger RR; Eechoute K; Mathijssen RH; Sleijfer S; Leijten F; Danser AH; van den Meiracker AH; Visser TJ
    J Clin Endocrinol Metab; 2011 Oct; 96(10):3087-94. PubMed ID: 21816788
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hypothyroidism after sunitinib treatment for patients with gastrointestinal stromal tumors.
    Desai J; Yassa L; Marqusee E; George S; Frates MC; Chen MH; Morgan JA; Dychter SS; Larsen PR; Demetri GD; Alexander EK
    Ann Intern Med; 2006 Nov; 145(9):660-4. PubMed ID: 17088579
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sunitinib-induced acute severe hypothyroidism in a case of metastatic gastrointestinal stromal tumor: A case report.
    Manir KS; Banerjee D; Bhowmick R; Roy C
    J Cancer Res Ther; 2018 Sep; 14(Supplement):S818-S819. PubMed ID: 30249914
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sunitinib induces hypothyroidism in advanced cancer patients and may inhibit thyroid peroxidase activity.
    Wong E; Rosen LS; Mulay M; Vanvugt A; Dinolfo M; Tomoda C; Sugawara M; Hershman JM
    Thyroid; 2007 Apr; 17(4):351-5. PubMed ID: 17465866
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Thyroid dysfunction in patients with advanced renal cell carcinoma treated with sunitinib: a multifactorial issue].
    Fuertes Zamorano N; De Miguel Novoa MP; Molino González A; Díaz Pérez JÁ; Rojas-Marcos PM; Montañez Zorrilla MC
    Endocrinol Nutr; 2010 Dec; 57(10):486-91. PubMed ID: 20702151
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thyroid Dysfunction in Patients with Metastatic Carcinoma Treated with Sunitinib: Is Thyroid Autoimmunity Involved?
    Pani F; Atzori F; Baghino G; Boi F; Tanca L; Ionta MT; Mariotti S
    Thyroid; 2015 Nov; 25(11):1255-61. PubMed ID: 26414109
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical characteristics of thyroid abnormalities induced by sunitinib treatment in Japanese patients with renal cell carcinoma.
    Sato S; Muraishi K; Tani J; Sasaki Y; Tokubuchi I; Tajiri Y; Yamada K; Suekane S; Miyajima J; Matsuoka K; Hiromatsu Y
    Endocr J; 2010; 57(10):873-80. PubMed ID: 20733268
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Summaries for patients. Underactive thyroid function after treatment with sunitinib for gastrointestinal cancer.
    Ann Intern Med; 2006 Nov; 145(9):I44. PubMed ID: 17088575
    [No Abstract]   [Full Text] [Related]  

  • 10. Thyrotoxicosis during sunitinib treatment for renal cell carcinoma.
    Grossmann M; Premaratne E; Desai J; Davis ID
    Clin Endocrinol (Oxf); 2008 Oct; 69(4):669-72. PubMed ID: 18394019
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sunitinib-induced thyrotoxicosis followed by persistent hypothyroidism with shrinkage of thyroid volume.
    Sakurai K; Fukazawa H; Arihara Z; Yoshida K
    Tohoku J Exp Med; 2010 Sep; 222(1):39-44. PubMed ID: 20814176
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tyrosine kinase inhibitors and the thyroid as both an unintended and an intended target.
    Vetter ML; Kaul S; Iqbal N
    Endocr Pract; 2008; 14(5):618-24. PubMed ID: 18753108
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sunitinib-induced autoimmune thyroiditis in a patient with metastatic renal cell carcinoma: a case report.
    Babacan T; Sevinc A; Akarsu E; Balakan O
    Chemotherapy; 2012; 58(2):142-5. PubMed ID: 22584361
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The clinical implications of sunitinib-induced hypothyroidism: a prospective evaluation.
    Wolter P; Stefan C; Decallonne B; Dumez H; Bex M; Carmeliet P; Schöffski P
    Br J Cancer; 2008 Aug; 99(3):448-54. PubMed ID: 18665181
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sunitinib-induced hyperammonemic encephalopathy in gastrointestinal stromal tumors.
    Lee NR; Yhim HY; Yim CY; Kwak JY; Song EK
    Ann Pharmacother; 2011 Oct; 45(10):e56. PubMed ID: 21954449
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sunitinib induces hypothyroidism with a markedly reduced vascularity.
    Makita N; Miyakawa M; Fujita T; Iiri T
    Thyroid; 2010 Mar; 20(3):323-6. PubMed ID: 20187785
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sunitinib: new drug. For some gastrointestinal stromal tumours.
    Prescrire Int; 2007 Aug; 16(90):138-41. PubMed ID: 17724833
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib.
    Rini BI; Tamaskar I; Shaheen P; Salas R; Garcia J; Wood L; Reddy S; Dreicer R; Bukowski RM
    J Natl Cancer Inst; 2007 Jan; 99(1):81-3. PubMed ID: 17202116
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sunitinib in patients with metastatic renal cell carcinoma.
    Motzer RJ; Rini BI; Bukowski RM; Curti BD; George DJ; Hudes GR; Redman BG; Margolin KA; Merchan JR; Wilding G; Ginsberg MS; Bacik J; Kim ST; Baum CM; Michaelson MD
    JAMA; 2006 Jun; 295(21):2516-24. PubMed ID: 16757724
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acute severe hypothyroidism induced by sunitinib.
    Prat A; Serrano C; Valverde C; Calvo E
    Radiother Oncol; 2008 Oct; 89(1):124-5. PubMed ID: 18502526
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.